Senior Dutch researcher sacked for manipulating data in rheumatoid arthritis drug trialBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f5267 (Published 23 August 2013) Cite this as: BMJ 2013;347:f5267
- Tony Sheldon
A senior researcher in rheumatology at a leading Dutch university hospital has been sacked after admitting manipulating data in a clinical trial for the past three years.
The Leiden University Medical Center has consequently halted the TIGER trial for which the researcher was responsible, a phase II patient study investigating the use of the drug omalizumab to treat rheumatoid arthritis (Anti-IgE therapy (omalizumab) in IgE-ACPA positive RA).
Publications based on fraudulent data, which appeared in the US Proceedings of the National Academy of Sciences (PNAS) in 2010 and the Annals of the Rheumatic Diseases in 2011 are in the process of being withdrawn. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial